SCHEMBL1695992

SCHEMBL1695992

N#Cc1cc(F)c(Cl)cc1OCCCc1cccc(N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.47
CYP2D6 P10635 2/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
NOS2 P35228 2/20 0.45
MAP3K8 P41279 1/20 0.41
FNTA P49354 3/20 0.39
FNTB P49356 3/20 0.39
PGGT1B P53609 3/20 0.39
MAOB P27338 3/20 0.36
MAOA P21397 2/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP19A1 P11511 1/20 0.35
GLA P06280 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
KHK P50053 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25413961 0.84 FNTA (0.43) MRGPRX4CYP2D6SLC6A2SLC6A4NOS2
SCHEMBL25409863 0.73 HDAC1 (0.43) FNTAFNTBPGGT1BMAOBMAOA
SCHEMBL1695991 0.70 NOS2 (0.62) MRGPRX4CYP2D6SLC6A2SLC6A4NOS2
SCHEMBL4485604 0.68 FNTA (0.55) FNTAFNTBPGGT1BMAOBMAOA
SCHEMBL27513303 0.67 SLC6A4 (0.42) MRGPRX4CYP2D6SLC6A2SLC6A4NOS2
SCHEMBL6981893 0.67 NOS2 (0.52) MRGPRX4CYP2D6SLC6A2SLC6A4NOS2
Hydrochloric Acid SCHEMBL27526757 0.67 SLC6A4 (0.43) MRGPRX4CYP2D6SLC6A2SLC6A4NOS2
SCHEMBL361193 0.66 ALDH1A1 (0.47) CYP2D6SLC6A2SLC6A4NOS2FNTA
SCHEMBL28855862 0.65 MAOB (0.61) MRGPRX4MAOBMAOAALDH1A1CYP19A1
SCHEMBL27807107 0.65 MAOB (0.39) MRGPRX4SLC6A4FNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131582-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES Vertex Pharmaceuticals Incorporated (US) 2017-02-22 EP disclosed
WO-2015160787-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-10-22 WO disclosed
EP-2748156-A1 NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA Boehringer Ingelheim International GmbH (DE) 2014-07-02 EP disclosed
EP-2736886-A1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2014-06-04 EP disclosed
EP-2731941-A1 NOVEL AND SELECTIVE CCR2 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2014-05-21 EP disclosed
EP-2721025-A1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-23 EP disclosed
EP-2576542-A1 CCR2 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2013-04-10 EP disclosed
EP-2569298-A1 NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-03-20 EP disclosed
EP-2569295-A1 NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-03-20 EP disclosed
WO-2013026797-A1 NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-28 WO disclosed
EP-2513086-A1 NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2012-10-24 EP disclosed
WO-2011147772-A1 CCR2 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 WO disclosed
WO-2011141477-A1 NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-17 WO disclosed
WO-2011141474-A1 NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-17 WO disclosed
EP-2379525-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD Boehringer Ingelheim International GmbH (DE) 2011-10-26 EP disclosed
WO-2011073155-A1 NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO disclosed
WO-2011073154-A1 NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO disclosed
WO-2010070032-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed
EP-2155689-A2 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2010-02-24 EP disclosed
WO-2008145681-A2 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 WO disclosed